Condition
Mass Balance Study
Total Trials
5
Recruiting
0
Active
1
Completed
4
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 4 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
5Total
P 1 (5)
Trial Status
Completed4
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07644442Phase 1CompletedPrimary
Study on [14C]HMPL-453（FGFR Inhibitor） in Healthy Chinese Adult Male Subjects
NCT07411742Phase 1Active Not RecruitingPrimary
Mass Balance Study of [14C] D-2570
NCT06671873Phase 1CompletedPrimary
Study on Mass Balance of [14C]HMPL-306（Isocitrate Dehydrogenase Inhibitor） in Healthy Chinese Adult Male Subjects
NCT06233916Phase 1CompletedPrimary
Mass Balance Study of [14C] D-1553 in Chinese Healthy Adult Male Subjects
NCT02126514Phase 1Completed
A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293
Showing all 5 trials